Cover Image
Market Research Report

Antibody Pipeline Database

Published by La Merie Publishing Product code 138240
Published Content info
Delivery time: 1-2 business days
Not Available
Back to Top
Antibody Pipeline Database
Published: November 23, 2010 Content info:

This publication has been discontinued on October 10, 2014.


Subscription to La Merie's proprietary Antibody Pipeline Database provides online access to more than 1,600 project entries for therapeutic antibodies on the market and in research & development. Each project is specified for its Target or Mechanism of Action, Therapeutic Area and R&D Phase. Use of the R&D database of therapeutic antibodies is intuitive. Data sets of interest can be printed and exported. Projects are being updated continuously. The R&D history of each project with online references of information sources can be viewed and printed. Sales figures of major products are provided. The projects can be segmented into Territories, Therapeutic Areas and R&D Phases. An advanced search function allows to combine search parameters. A scroll down menu for predefined targets conveniently selects projects of interest. By clicking on column heads of the project list, projects can be arranged in ascending or descending alphabetical or numerical order, e.g. for phase, product category or company name. Sample screenshots illustrate the database.

Purchase of the subscription provides a 1-year online access to the data of the Antibody Pipeline Database.

Benefits from the Antibody Pipeline Database:

  • New database with no historical burden
  • Intuitive use
  • Designed for structured searches
  • Focused on targets, therapeutic areas and R&D phases
  • Ideal for competitor analysis (companies, targets, product categories)
  • Cost-effective and rapid solution for benchmarking
  • Identification of licensing candidates

Project listing in a tabular format:

  • Drug Codes
  • Target / Mechanism of Action
  • Class of Compound
  • Product Category
  • Company
  • Territory
  • Therapeutic Area
  • Indication
  • R&D Phase

Therapeutic Areas:

  • Cardiovascular & blood
  • Dermatology
  • Gastrointestinal
  • Genitourinary, renal & gynecology
  • Infectious & toxicology
  • Metabolism & endocrine
  • Neurology & psychiatry
  • Oncology
  • Ophthalmology & otorhinolaryngology
  • Orthopedics, dental, anesthesia & surgery
  • Pulmonary & respiratory
  • Rheumatoid & autoimmune

Predefined Targets of the Scroll Down Menu:

  • Anti-Infective Antibodies
  • Antibody-Drug Conjugates (ADC)
  • Biosimilar & Biobetter/Biosuperior Antibodies
  • c-MET/HGF Inhibitors
  • CD3 Antagonists
  • CD19 Antagonists
  • CD20 Antibodies
  • CD22 Antibodies
  • CD30 Antibodies
  • CD40/L
  • CEA Antibodies
  • Death Receptors TRAIL-R1/2
  • EGF-R Agonists and Antagonists
  • EpCAM Antagonists
  • GM-CSF Antibodies
  • Her2 Antagonists
  • IGF-1R Antagonists
  • Immunocytokines
  • Immunotoxins
  • Interleukin-1/R Antagonists
  • Interleukin-6/R Antagonists
  • Interleukin-12/23 Antagonists
  • Interleukin-13 Antagonists
  • Interleukin-17 Antagonists
  • Integrin Antagonists
  • NGF Antagonists
  • PDGF-R Agonists and Antagonists
  • TGF-R Agonists and Antagonists
  • TNF Antagonists
  • TRAIL-R1/R2 (Death Receptors)
  • VEGF and VEGF-R Agonists and Antagonists

Back to Top